Treatment
Leflunomide clinical trials
We’re tracking 18 recruiting studies that include Leflunomide, each written for real people, not researchers, below.
Recruiting studies
- NCT02714634RecruitingPhase 4
Methotrexate or leflunomide plus added therapy for rheumatoid arthritis
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
StrasbourgAges 18 years+ - NCT05937191RecruitingPhase 1/Phase 2
Leflunomide for childhood idiopathic lung bleeding
This trial tests whether leflunomide can safely help children with idiopathic pulmonary hemosiderosis (a condition where the lungs bleed, and iron builds up). The study is mainly about safety and early signs of benefit in young patients.
Guangzhou, GuangdongAges 5 months–18 years - NCT06923488RecruitingPhase 1/Phase 2
Leflunomide and decitabine for returning MDS
This trial tests a new combination of two drugs—leflunomide and decitabine—for people with MDS that has come back or hasn't responded to treatment. The goal is to see if this combination can help control the disease.
Morgantown, West VirginiaAges 18 years+ - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT07388407Recruiting
Genetics of leflunomide for rheumatoid arthritis
This study looks at how your genes might affect how well leflunomide works for rheumatoid arthritis. It is for Pakistani adults who are starting or recently started leflunomide, and will help doctors understand who might respond best.
Islamabad, Punjab ProvinceAges 20–65 - NCT07709013RecruitingPhase 2
Leflunomide to stop CMV after stem cell transplant
This study tests whether the drug leflunomide can prevent CMV virus reactivation after a half-matched stem cell transplant. If you have already had a successful white blood cell recovery and no sign of CMV, this might help keep you safe from the virus.
Navi Mumbai, MaharashtraAges 18 years+ - NCT04508790RecruitingPhase 2
Leflunomide plus pomalidomide with dexamethasone for relapsed myeloma
This trial studies whether a combination of three medicines (leflunomide, pomalidomide, and dexamethasone) can better treat multiple myeloma that has come back or stopped responding. It may help people who are not good candidates for transplant and who have measurable disease.
Duarte, CaliforniaAges 18 years+ - NCT05113004RecruitingPhase 2
Testing new outcomes in primary Sjögren’s syndrome
This Phase 2 study tests how to measure changes in primary Sjögren’s syndrome symptoms and body activity. It may help researchers confirm which outcomes best reflect improvement and how different patient types respond to treatment.
BrestAges 18 years+ - NCT05937880Recruiting
Leflunomide for kids with stubborn Henoch-Schonlein purpura rash
This trial looks at whether leflunomide can calm Henoch-Schonlein purpura (a childhood rash condition) when the rash is hard to control. If standard treatments don’t stop new or worsening rash, this study may offer another option.
Guangzhou, GuangdongAges 1–18 - NCT06229340RecruitingPhase 2
Two drug combinations for advanced cancer with RAS mutations
This trial tests two different treatment combinations (leflunomide alone or with MEK inhibitor and hydroxychloroquine) in people with advanced cancer that has a RAS mutation and has not responded to at least two prior therapies.
Saint PetersburgAges 18–85 - NCT06454383RecruitingPhase 1
Gemcitabine and leflunomide for advanced pancreatic cancer
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Duarte, CaliforniaAges 18 years+ - NCT06540937RecruitingPhase 2
Leflunomide for MEN-1 related neuroendocrine tumors
This trial tests if leflunomide, a medication usually used for arthritis, can shrink or slow the growth of neuroendocrine tumors in people with MEN-1 gene mutations. It is for patients whose tumors have worsened after standard treatment.
BeijingAges 18–75 - NCT04725422Recruiting
Registry for children with nonbacterial bone inflammation
This study collects medical information (and imaging results) from children and teens with nonbacterial bone inflammation. It may help doctors better understand how this condition looks on scans and how it’s diagnosed, especially to rule out infection or cancer.
Seattle, WashingtonAges Up to 21 years - NCT03414502RecruitingPhase 3
Predictors of Response to DMARDs in Rheumatoid Arthritis
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
Omaha, NebraskaAges 19 years+ - NCT05626348RecruitingPhase 4
Test immune-modulator treatments for rheumatoid arthritis with knee trouble
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
Jinan, ShandongAges 18–80 - NCT05789030Recruiting
Treating IgG4-related disease with mild steroid starts
This trial is studying treatment plans for people with IgG4-related disease that affects a surface (superficial) organ area. It focuses on people who are newly diagnosed or have come back and who need to start or continue steroid medicine at a low dose.
BeijingAges 18–75 - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+
What Leflunomide is being studied for
Conditions with recruiting Leflunomide studies.
Common questions
- Are there clinical trials studying Leflunomide?
- Yes. Clin2 currently lists 18 recruiting studies that include Leflunomide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Leflunomide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Leflunomide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Leflunomide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.